Adam C Palmer
Adam C Palmer
Assistant Professor, UNC-Chapel Hill
Verified email at
Cited by
Cited by
Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy
AC Palmer, PK Sorger
Cell 171 (7), 1678-1691. e13, 2017
Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors
S Goel, Q Wang, AC Watt, SM Tolaney, DA Dillon, W Li, S Ramm, ...
Cancer cell 29 (3), 255-269, 2016
Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance
AC Palmer, R Kishony
Nature Reviews Genetics 14 (4), 243-248, 2013
Transcriptional interference by RNA polymerase pausing and dislodgement of transcription factors
AC Palmer, JB Egan, KE Shearwin
Transcription 2 (1), 9-14, 2011
Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes
AC Palmer, E Toprak, M Baym, S Kim, A Veres, S Bershtein, R Kishony
Nature communications 6 (1), 7385, 2015
Opposing effects of target overexpression reveal drug mechanisms
AC Palmer, R Kishony
Nature Communications 5, 2014
A Mathematical Model for Transcriptional Interference by RNA Polymerase Traffic in Escherichia coli
K Sneppen, IB Dodd, KE Shearwin, AC Palmer, RA Schubert, BP Callen, ...
Journal of Molecular Biology 346 (2), 399-409, 2005
Independent drug action in combination therapy: implications for precision oncology
D Plana, AC Palmer, PK Sorger
Cancer discovery 12 (3), 606-624, 2022
Potent transcriptional interference by pausing of RNA polymerases over a downstream promoter
AC Palmer, A Ahlgren-Berg, JB Egan, IB Dodd, KE Shearwin
Molecular Cell 34 (5), 545-555, 2009
A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity
AC Palmer, C Chidley, PK Sorger
Elife 8, e50036, 2019
Chemical decay of an antibiotic inverts selection for resistance
AC Palmer, E Angelino, R Kishony
Nature Chemical Biology 6 (2), 105-107, 2010
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
Y He, R Koch, V Budamagunta, P Zhang, X Zhang, S Khan, D Thummuri, ...
Journal of hematology & oncology 13, 1-13, 2020
Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors
AC Palmer, B Izar, H Hwangbo, PK Sorger
Clinical Cancer Research 28 (2), 368-377, 2022
Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming
H Wang, RP Sheehan, AC Palmer, RA Everley, SA Boswell, N Ron-Harel, ...
Cell systems 8 (5), 412-426. e7, 2019
Drug independence and the curability of cancer by combination chemotherapy
AE Pomeroy, EV Schmidt, PK Sorger, AC Palmer
Trends in cancer 8 (11), 915-929, 2022
Pervasive selection for and against antibiotic resistance in inhomogeneous multistress environments
R Chait, AC Palmer, I Yelin, R Kishony
Nature communications 7 (1), 10333, 2016
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
R Koch, AL Christie, JL Crombie, AC Palmer, D Plana, K Shigemori, ...
Blood, The Journal of the American Society of Hematology 133 (6), 566-575, 2019
Nonoptimal gene expression creates latent potential for antibiotic resistance
AC Palmer, R Chait, R Kishony
Molecular biology and evolution 35 (11), 2669-2684, 2018
The role of repressor kinetics in relief of transcriptional interference between convergent promoters
N Hao, AC Palmer, A Ahlgren-Berg, KE Shearwin, IB Dodd
Nucleic Acids Research 44 (14), 6625-6638, 2016
Torin2 exploits replication and checkpoint vulnerabilities to cause death of PI3K-activated triple-negative breast cancer cells
SS Chopra, A Jenney, A Palmer, M Niepel, M Chung, C Mills, ...
Cell systems 10 (1), 66-81. e11, 2020
The system can't perform the operation now. Try again later.
Articles 1–20